The Gut-Brain Axis: Alpha Synuclein Pathology and Its Role in Parkinson's Disease

Parkinson's disease is a chronic neurodegenerative disorder characterized by motor symptoms like tremors, bradykinesia, and rigidity, along with non-motor symptoms such as cognitive decline and autonomic dysfunction. The disease's prevalence increases with age, particularly affecting individuals over 60. Alpha-synuclein, a presynaptic nerve protein implicated in PD's pathogenesis involves the formation of Lewy bodies and neurites. Studies indicate that Lewy bodies could arise from the enteric nervous system, migrating to central dopaminergic neurons through the gut-brain axis. This suggests that changes in gut microbiota might affect the disease's progression development. The pathogenesis of PD involves complex interactions between genetic, environmental, and biochemical factors leading to dopaminergic cell degeneration. The accumulation of Lewy bodies contributes to oxidative stress and neuronal dysfunction, affecting both motor and non-motor symptoms. Recent research emphasizes the significance of the gut microbiome in Parkinson's disease (PD), noting that dysbiosis is associated with inflammation and neurodegeneration. In PD patients, enhanced intestinal permeability and inflammatory bacteria have been observed patients. Understanding these mechanisms may reveal new therapeutic strategies to slow or prevent PD progression, underscoring the importance of gut health in neurodegenerative diseases. This article provides a narrative review examining recent literature on the gut-brain axis and alpha-synuclein pathology in Parkinson's disease, emphasizing both pathophysiological mechanisms and potential therapeutic insights.